The Illusion of Recovery From Atrial Fibrillation, a Review of Postcardioversion Anticoagulation Guidelines

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice and an independent, well-established risk factor for ischemic stroke. However, restoring sinus rhythm via cardioversion does not eliminate this risk. Cardioversion itself transiently increases thromboembolic risk more than 10-fold, driven by atrial stunning, a state in which the left atrium and left atrial appendage remain mechanically dysfunctional despite normalized electrical activity seen on an electrocardiogram. Retrospective data show that thromboembolic events are clustered heavily within the first 2 weeks postcardioversion, supporting the near-universal recommendation of at least 4 weeks of continued therapeutic anticoagulation postcardioversion for AF duration more than 12 to 48 hours, regardless of baseline stroke risk score. Beyond this initial 4-week recommendation, the decision to continue anticoagulation is based on a comprehensive assessment of the patient's thromboembolic risk profile, rather than rhythm status or cardioversion success. Multiple trials have demonstrated a significant increase in the incidence of ischemic strokes in patients who had a premature discontinuation of anticoagulation postcardioversion. Additionally, having a prior stroke, the heaviest weighted risk-stratification variable, favors indefinite anticoagulation regardless of postcardioversion rhythm outcome. Current guidelines provide a framework for approaching postcardioversion anticoagulation, including a fixed 4-week anticoagulation course encompassing the atrial stunning period, followed by individualized risk-stratification to determine the indication for continued anticoagulation. Nevertheless, future research is still required to better elucidate whether anticoagulation can be safely discontinued after completion of the recommended 4-week postcardioversion anticoagulation course in patients with a prior AF-related stroke.